EPISODE · Feb 9, 2026 · 7 MIN
GT Biopharma Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND>
from ABN Newswire Finance Video · host ABN Newswire
GT Biopharma, Inc. (NASDAQ:GTBP) continues to advance its platform-based immuno-oncology strategy following recent FDA clearance of an Investigational New Drug (IND) application for GTB-5550 targeting solid tumors.>
What this episode covers
GT Biopharma, Inc. (NASDAQ:GTBP) continues to advance its platform-based immuno-oncology strategy following recent FDA clearance of an Investigational New Drug (IND) application for GTB-5550 targeting solid tumors.>
NOW PLAYING
GT Biopharma Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND>
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m